Expert Rev Gastroenterol Hepatol. 2012;6(4):481-495. T1 Tumor involving biliary confluence ± unilateral extension to second-order biliary radicles T2 Tumor involving biliary confluence ± ...

T1 Tumor involving biliary confluence ± unilateral extension to second-order biliary radicles T2 Tumor involving biliary confluence ± unilateral extension to second-order biliary and ipsilateral ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Biliary fibrosis is the process of periportal scarring within the liver that is caused by diseased bile ducts. It often progresses to end-stage liver disease. Currently, liver transplantation is the ...

A rabies clinic will be held from 11 a.m. to 12 p.m. April 26 at the Confluence Community Center, 711 Logan Place. A fee will be charged. All pets must be leashed or in a carrier. Bring the ...

Tovecimig combined with paclitaxel showed a 17.1% response rate in biliary tract cancer, outperforming paclitaxel alone. The COMPANION-002 study reported lower progressive disease rates with tovecimig ...

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy, the first ...

Topline data were announced from a phase 2/3 trial evaluating tovecimig in combination with paclitaxel in patients with unresectable advanced, metastatic or recurrent biliary tract cancers (BTC).

Primary biliary cholangitis (PBC) is an autoimmune disorder that leads to the destruction of bile ducts within the liver. As more bile ducts become lost and damaged, bile acids build up within the ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

The primary end point of overall response rate has been met in the COMPANION-002 trial of tovecimig and paclitaxel in advanced biliary tract cancer. In patients with advanced biliary tract cancer who ...